New Delhi: The Russian Covid-19 vaccine–Sputnik V vaccine was found to more efficient against the highly transmissible Delta variant of coronavirus disease, which was first found in India, according to the Gamaleya Center study submitted for publication in an international peer-reviewed journal.
“Sputnik V is more efficient against the Delta variant of coronavirus, first detected in India than any other vaccine that published results on this strain so far – the Gamaleya Center study submitted for publication in an international peer-reviewed journal,” said Russian Direct Investment Fund (RDIF) in a tweet on Tuesday.
BREAKING | RDIF: “#SputnikV is more efficient against the Delta variant of coronavirus, first detected in India than any other vaccine that published results on this strain so far – the Gamaleya Center study submitted for publication in an international peer-reviewed journal.” pic.twitter.com/XrwnGNhiNE
— Sputnik V (@sputnikvaccine) June 15, 2021
Sputnik V, developed by Russia’s Gamaleya Institute, is reported to show 91.6 per cent efficacy against Coronavirus and has been authorised in 67 countries across the world. On June 10, the RDIF during a campaign in Bahrain claimed that Sputnik V has estimated the efficacy of 94.3 per cent. However, the World Health Organisation is yet to approve Sputnik as an emergency vaccine.
The Drug Controller General of India (DCGI) on April 13 approved the use of the Russian Sputnik V, making it the third vaccine to get regulatory approval in the country. A Subject Expert Committee (SEC) met to discuss Russia’s Sputnik V application for emergency use authorisation in India. The committee of experts later gave their recommendations and sent DCGI for a final nod on April 12.
“Over 850 million doses of Sputnik V are going to be produced in India annually sufficient to vaccinate more than 425 million people around the world,” said Kirill Dmitriev, CEO of the Russian Direct Investment Fund in a statement on April 13.
The DCGI later on June 4 allowed the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test, and analysis with certain conditions.
Back in September 2020, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India.
Sputnik V uses two different vectors for the two shots in a course of vaccination.
Its efficacy was determined to be 91.6 per cent as per a published article in the medical journal Lancet. RDIF has reached agreements with the pharmaceutical companies in India like Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce more than 850 million doses per year.